TY - JOUR
T1 - Inhibition of angiogenesis
T2 - Treatment options for patients with metastatic prostate cancer
AU - Figg, William D.
AU - Kruger, Erwin A.
AU - Price, Douglas K.
AU - Kim, Sonia
AU - Dahut, William D.
N1 - Funding Information:
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
PY - 2002
Y1 - 2002
N2 - Prostate cancer is the most frequently diagnosed malignancy and the second most common cause of cancer-related death in men in the United States. Unfortunately, at the current time, no curative treatments are available for metastatic prostate cancer. As is the case for most solid tumors, the recruitment of blood vessels (angiogenesis) is key for the progression and metastasis of prostate cancer. Inhibition of this process is an attractive approach to treatment. Many antiangiogenic agents are currently in clinical development. The following discussion will outline the importance of angiogenesis in the metastasis and progression of prostate cancer, summarize the current surrogate markers of angiogenesis available for the drug development of antiangiogenic agents, and review examples of investigational agents that target tumor angiogenesis (e.g., TNP-470, Thalidomide, CC5013, Carboxyamido-triazole (CAI), Endostatin, SU5416, SU6668, Bevacizumab (Anti-VEGF rhuMAb), and 2-Methoxyestradiol).
AB - Prostate cancer is the most frequently diagnosed malignancy and the second most common cause of cancer-related death in men in the United States. Unfortunately, at the current time, no curative treatments are available for metastatic prostate cancer. As is the case for most solid tumors, the recruitment of blood vessels (angiogenesis) is key for the progression and metastasis of prostate cancer. Inhibition of this process is an attractive approach to treatment. Many antiangiogenic agents are currently in clinical development. The following discussion will outline the importance of angiogenesis in the metastasis and progression of prostate cancer, summarize the current surrogate markers of angiogenesis available for the drug development of antiangiogenic agents, and review examples of investigational agents that target tumor angiogenesis (e.g., TNP-470, Thalidomide, CC5013, Carboxyamido-triazole (CAI), Endostatin, SU5416, SU6668, Bevacizumab (Anti-VEGF rhuMAb), and 2-Methoxyestradiol).
KW - Antiangiogenesis
KW - Cancer therapy
KW - Clinical trials
KW - Prostate carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0036282502&partnerID=8YFLogxK
U2 - 10.1023/A:1015626410273
DO - 10.1023/A:1015626410273
M3 - Review article
C2 - 12099578
AN - SCOPUS:0036282502
SN - 0167-6997
VL - 20
SP - 183
EP - 194
JO - Investigational New Drugs
JF - Investigational New Drugs
IS - 2
ER -